NEW YORK, July 10 (Reuters) - Insmed Inc said on Thursday its version of Amgen Inc's drug Neupogen, for boosting white blood cells, showed equivalence in a small study, moving Insmed closer to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback